Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Leiner & loratadine

This article was originally published in The Tan Sheet

Executive Summary

Company's "goal is to create marketing programs to enable [its loratadine] retail private label sales to exceed 30% of the market," which it anticipates "to be $500 mil.," firm says. Leiner expects to ship its generic version of Schering-Plough's OTC Claritin in mid-July (1"The Tan Sheet" Feb. 10, 2002, p. 8). Company notes it will support initial loratadine offering by conducting "in-store promotions and regional advertising in conjunction with [its] retail consumers." Leiner will consider manufacturing, marketing other forms of loratadine at a later date, firm adds, noting that, overall, it expects "to introduce into the market new innovative products...that will generate $100 mil. in gross sales" in 2003...
Advertisement
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS095136

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel